Adriamycin
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Explore 20 assets in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Northwestern University
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05202782CT.gov Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04799275CT.gov Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Northwestern University | P2/3 | BB · 64 |
| Prednisone | Northwestern University | P2/3 | BB |
| Vincristine Sulfate | Northwestern University | P2/3 | BB |
| Cyclophosphamide | Mayo Clinic | P2/3 | B |
| Rituximab | Mayo Clinic | P2/3 | B |
| Recombinant Human Hyaluronidase | National Cancer Institute (NCI) | P2/3 | B |
| Lenalidomide | David Bond, MD | P2 | B |
| Azacitidine | National Cancer Institute (NCI) | P2/3 | B |
| Pembrolizumab | Mayo Clinic | P2 | CCC |
+11 more in the Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →